Encara no tenim significats per a "major bleeding".
1No serious or major bleeding-related adverse events were reported during either study.
2The primary safety outcome was major procedure-related complications and major bleeding events.
3There were neither thrombotic or major bleeding events nor major side effects.
4Among major bleeding events, only those also classified as severe increased mortality.
5The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred.
6No major bleeding was recorded, and no patient died during the study.
7During surgery there was no major bleeding and no transurethral resection syndrome.
8The presence of renal failure represents an independent predictor for major bleeding.
9Risk of major bleeding was also similar to the target trial.
10However, there were no associations with the risk of stroke or major bleeding.
11Hypertension does not appear to significantly increase the risk of major bleeding complications.
12Non-statistically significant differences were observed in major bleeding events or mortality.
13End points included major cardiovascular events, total mortality, and major bleeding.
14Conclusion: The overall incidence of major bleeding after percutaneous biopsy is very low.
15The primary safety endpoint was a composite of vascular complications and major bleeding.
16The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding.
Aquesta col·locació està formada per:
Major bleeding a través del temps
Major bleeding per variant geogràfica